Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed: Sanofi India Ltd - 500674 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)
The unaudited financial results of the Company for the quarter and half year ended 30th June 2021 were approved by the Board of Directors of the Company at its meeting held on 27th July 2021 and published on 29th July 2021. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 30th June 2021 in the format specified in the applicable accounting standards. Kindly take the above information on record. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed: Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Dear Sirs, As required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr. Girish Tekchandani has resigned from the position of Company Secretary (Key Managerial Personnel) and Compliance Officer of the Company to pursue other opportunities outside of Sanofi. The resignation has been accepted and he will be relieved from his responsibilities at the end of business hours on 31st August 2021. The successor of Mr. Girish Tekchandani will be announced separately. Pursuant to Regulation 6 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Vaibhav Karandikar, Whole Time Director and Chief Financial Officer (ACS No. 13110) will be the Compliance Officer of the Company with effect from 1st September 2021, till further announcement on this matter. Request you to take above information on record.
Sanofi bets big on mRNA vaccines, to buy Translate Bio for $3.2 bn
The firm said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion
Sanofi India sells nutraceuticals biz to Kedaara-Universal Medicare for 587 cr
Sanofi said 16 nutraceutical brands in the portfolio, including Seacod, E-Cod, CoQ, Primosa and Collaflex, would be transferred to Universal Nutriscience as part of the transaction Sanofi India Ltd - 500674 - Slump Sale And Transfer Of The Nutraceuticals Business Of The Company
Please find enclosed announcement related to - Slump Sale and transfer of the Nutraceuticals business of the Company which is self explanatory for your records Sanofi India Ltd - 500674 - Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2021
We refer to our letter dated 12th July 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.30 a.m. and concluded at 1.45 p.m. The Board approved unaudited financial results for the quarter and half year ended 30th June 2021. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and half year ended 30th June 2021 approved at this Meeting including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flow for the half year ended 30th June 2021 along with a copy of the Limited Review Report duly signed by the Auditors of the Company. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Shareholding for the Period Ended June 30, 2021
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here